EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, Biological Evaluation and Molecular Docking Study of New 1,3,4‐Thiadiazole‐Based Compounds as EGFR Inhibitors

Marwa I Serag iD, Samar S Tawfik, Hassan M Eisa, Sahar M I Badr

Drug Development Research · 2025-02 · 86 (1)

DOI: 10.1002/ddr.70035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 24.12.2024. Verfasst von Marwa I Serag und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. Hauptthemen laut MEDLINE: ErbB Receptors, Molecular Docking Simulation, Thiadiazoles, Drug Design. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 59 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Five series of new 1,3,4‐thiadiazole hybrids were designed and synthesized as promising EGFR inhibitors. Three human cancer cell lines were employed for testing each hybrid's in vitro antiproliferative efficacy; colon HCT‐116, liver HepG‐2 and breast MCF‐7 using MTT assay. Comparing compound 9a to the reference doxorubicin, 9a shown superior activity to that of Dox with respect to MCF‐7 (IC 50 3.31 µM) while being secure for normal cells WI‐38 (IC 50 = 43.99 µM). Further evaluation of the EGFR inhibitory activity of the most active candidates— 4a, 6b , 8b, 9a , and 9 d —was performed. Of them, compounds 9a and 8b demonstrated the highest IC 50 values, 0.08 and 0.15 µM, respectively, relative to the reference gefitinib (IC 50 = 0.04 µM). Subsequent mechanistic analysis of compound 9a revealed a notable 14.24‐fold increase in overall apoptosis and a 28.92% cell cycle arrest at G2/M. Additionally, research on apoptosis demonstrated that it triggered the mitochondrial apoptotic pathway. In MCF‐7 cells, it also led to an increase in ROS buildup. For the most powerful EGFR inhibitors, 9a and 8b , a molecular docking research was conducted, and all of the findings agreed with the biological findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsMolecular Docking SimulationThiadiazolesDrug DesignAntineoplastic AgentsProtein Kinase InhibitorsApoptosisHumansCell ProliferationMCF-7 CellsCell Line, TumorStructure-Activity RelationshipDrug Screening Assays, AntitumorHep G2 Cells

Stichwörter der Autor:innen

EGFR kinaseanticancer activitydocking studiesthiadiazole

Substanzen

ErbB ReceptorsThiadiazolesAntineoplastic AgentsEGFR protein, human1,3,4-thiadiazoleProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
  • Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura National University, Gamasa, Egypt.

ORCID-Profile: Marwa I Serag

Zitieren

APA

Serag, M. I., Tawfik, S. S., Eisa, H. M., & Badr, S. M. I. (2025). Design, Synthesis, Biological Evaluation and Molecular Docking Study of New 1,3,4‐Thiadiazole‐Based Compounds as EGFR Inhibitors. Drug Development Research, 86(1). https://doi.org/10.1002/ddr.70035

Vancouver

Serag MI, Tawfik SS, Eisa HM, Badr SMI. Design, Synthesis, Biological Evaluation and Molecular Docking Study of New 1,3,4‐Thiadiazole‐Based Compounds as EGFR Inhibitors. Drug Development Research. 2025;86(1). doi:10.1002/ddr.70035

BibTeX
@article{Serag2025,
  author = {Serag, Marwa I and Tawfik, Samar S and Eisa, Hassan M and Badr, Sahar M I},
  title = {Design, Synthesis, Biological Evaluation and Molecular Docking Study of New 1,3,4‐Thiadiazole‐Based Compounds as EGFR Inhibitors},
  journal = {Drug Development Research},
  year = {2025},
  volume = {86},
  number = {1},
  doi = {10.1002/ddr.70035}
}
Kostenlos starten →